First Biologic to Receive Orphan Drug Status for Ocular Graft-Vs.-Host Disease Dry Eye ATLANTA, GA –Feb. 26, 2020 – Cambium Medical Technologies (Cambium), a clinical stage company developing novel processed platelets for therapeutic applications, announced today that the U.S. Food & Drug Administration (FDA) has granted the company orphan drug designation for its fibrinogen-depleted human ...

Study Evaluating Standardized, Novel, Enriched, Allogeneic Serum Drop for Ocular Graft-vs.-Host Disease ATLANTA, GA – Feb. 20, 2020 – Cambium Medical Technologies (“Cambium”), a clinical stage company developing novel processed platelets for various therapeutic applications, announced the final patient was enrolled in Dec. 2019 for its Elate Ocular® topical fibrinogen-depleted human platelet lysate biologic in ...